Bergenbio ’s Bemcentinib Selected To Be Fast-Tracked As Potential Treatment For Covid-19 Through New National UK Government Clinical Trial Initiative

Bergen, Norway, 28 April 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, announces that bemcentinib has been selected as the first...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials